Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Real-world Outcomes of Favipiravir in Mild to Moderate COVID-19 with Single Outpatient Visit and Home Isolation
TCTR20221113004Completed
- Sponsor
- Chulabhorn Royal Academy
- Start
- Apr 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Trial of favipiravir in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Chulabhorn Royal Academy. Started Apr 2021; status: completed.
02
Drugs
favipiravir
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on TCTR20221113004.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20221113004.